Efficacy and Safety of Two Secukinumab Dose Regimens

ID# NCT03713619


Recruitment Status: Recruiting

Estimated Study Completion Date: February 16, 2022

HS Connect listed this: October 2020


Sponsor: Novartis Pharmaceuticals

Information provided by (Responsible Party): Novartis ( Novartis Pharmaceuticals )


Brief Summary:


The purpose of this study is to demonstrate superiority of secukinumab at Week 16, based on Hidradenitis Suppurativa Clinical Response (HiSCR) rates versus placebo, along with the maintenance of efficacy of secukinumab at Week 52 in subjects with moderate to severe HS. Moreover, this study will also assess the safety and tolerability of secukinumab.


Please link for complete details on this trial:






116 locations to include international. Please see link above for all location details and to confirm your location is recruiting.


Contact Information: 


Contact: Novartis Pharmaceuticals Phone: 1-888-669-6682 or +41613241111


Email: novartis.email@novartis.com


© 2021 by HS Connect, LLC  |  HSConnect.org@gmail.com  |  PO Box 73244 Puyallup, WA 98373  |  253.256.1579